Geriatria
Diretrizes para intervenções no tratamento de dor lombar aguda e crônica.
30 Nov, 2021 | 12:17h
Comentário no Twitter
The NEW #ClinicalPracticeGuideline for November …
Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021
Lots of debate already this week – access and make your own mind up here 👉 https://t.co/agqYNexJjA#yourJOSPT #LowBackPain pic.twitter.com/AnY8ily1w1
— JOSPT Community (@JOSPT) November 6, 2021
Revisão sistemática | Quantificação do impacto anticolinérgico e sedativo em idosos com polifarmácia.
26 Nov, 2021 | 11:52h
Comentário no Twitter
Systematic review of risk scales for anticholinergic burden and sedative overload – authors developed a comprehensive table on anticholinergics & sedatives (with potency). Check Table 2 and Table S2 (supplementary) for usable info to guide decision-making!https://t.co/JYaSuOeHqv
— Deprescribing (@Deprescribing) November 25, 2021
Opinião | Coisas que fazemos sem motivo: prescrever estimulante de apetite para idosos internados com perda de peso não intencional.
26 Nov, 2021 | 11:39hTrês sociedades neurológicas, incluindo a AAN, emitem forte diretriz de posicionamento sobre o aducanumabe.
24 Nov, 2021 | 11:25hConteúdos relacionados:
Editorial: Aducanumab for Alzheimer’s disease?
FDA approvement of Alzheimer’s drug sparks controversy among doctors.
Comentário no Twitter
Decisions With Patients and Families Regarding #Aducanumab in Alzheimer Disease, With Recommendations for Consent—Read the full AAN @AANMember Position Statement: https://t.co/ckoIVRi4DE #Neurology pic.twitter.com/q8TSU67zm9
— Neurology Journal (@GreenJournal) November 19, 2021
Análise de segurança de estudos randomizados mostrou que o aducanumabe (medicamento para Alzheimer) causou edema cerebral em 35% dos pacientes e sintomas associados (cefaleia, confusão, tontura e náusea) em 26%.
24 Nov, 2021 | 11:24hComentário: Biogen Alzheimer’s drug shows brain swelling in 35% of patients – MedicalXpress
Comentário no Twitter
Amyloid-related imaging abnormalities occurred in ~ 40% of participants in the phase 3 studies of aducanumab. Approximately one-quarter of patients with amyloid-related imaging abnormalities experience symptoms https://t.co/TnUPXT686l
— JAMA Neurology (@JAMANeuro) November 22, 2021
Revisão | Prevenção e tratamento da fibrilação atrial via modificação de fatores de risco.
24 Nov, 2021 | 11:11hRevisão sistemática | Inibidores seletivos de recaptação da serotonina (ISRS) na recuperação pós-AVC.
24 Nov, 2021 | 11:07hResumo: Selective serotonin reuptake inhibitors for stroke recovery – Cochrane Library
Artigo original: Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery – Cochrane Library
Conteúdos relacionados:
RCT: Routine treatment with fluoxetine does not reduce the incidence of depression after stroke.
[Abstract Only] Randomized trial: Fluoxetine does not improve functional recovery after acute stroke
Randomized Trial: Effects of Fluoxetine on Functional Outcomes After Acute Stroke
Comentário no Twitter
Selective #serotonin reuptake inhibitors for #stroke recovery https://t.co/7R5bijz49e Updated @CochraneStroke systematic review: 'reduced risk of future depression by about a quarter, but led to a slight increase in the risk of seizures & increased the risk of bone fractures.'
— The Cochrane Library (@CochraneLibrary) November 19, 2021
M-A | Evidências atuais não suportam a redução intensiva da pressão arterial como estratégia preventiva de declínio cognitivo e demência.
23 Nov, 2021 | 15:38h
Comentário no Twitter
Meta-analysis found no associated reduction in the risk of cognitive decline with intensive as compared to standard blood pressure (BP) interventions. There is insufficient evidence to support intensive BP management to prevent cognitive impairment. https://t.co/2BEV1ywrCO
— JAMA Network Open (@JAMANetworkOpen) November 22, 2021
Orientação EuGMS | Tratamento de pacientes com COVID-19 pós-aguda na reabilitação geriátrica.
22 Nov, 2021 | 09:37hConteúdos relacionados:
Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)
Revisão sistemática | Pré-habilitação e reabilitação nas artroplastias.
22 Nov, 2021 | 09:10hVer também: